Tuberculosis in patients with haematological malignancies by Anibarro, L. & Pena, A.
Mediterr J Hematol Infect Dis 2014; 6; Open Journal System  
  
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES 
www.mjhid.org ISSN 2035-3006 
 
 
Review Article  
 









 Unidad de tuberculosis. Servicio de Medicina Interna. Complexo Hospitalario de Pontevedra, 36001-Pontevedra, 
Galicia, Spain 
2
 Instituto de Investigación Biomédica de Vigo (IBIV). Vigo, Spain. 
 
Correspondence to: Dr. Luis Anibarro. Unidad de tuberculosis. Servicio de Medicina Interna. Complexo 
hospitalario de Pontevedra. 36001-Pontevedra, Galicia, Spain. E-mail: luis.anibarro.garcia@sergas.es  
 
Competing interests: The authors have declared that no competing interests exist. 
 
Published: April 7, 2014 
Received: November 14, 2013 
Accepted: March 10, 2014 
Citation: Mediterr J Hematol Infect Dis 2014, 6(1): e2014026, DOI: 10.4084/MJHID.2014.026 
This article is available from: http://www.mjhid.org/article/view/12474  
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited.  
  
Abstract. Tuberculosis (TB) is an infectious disease that causes more than 1 million deaths 
worldwide every year. In addition, it is estimated that one third of the world population is infected 
with M. tuberculosis in a latent state, which involves an eventual risk of progressing to active TB 
disease. Patients with immunodeficiencies, such as those suffering from haematological 
malignancies, have a greater risk of progressing to TB disease once infected. It is estimated that the 
Relative Risk of TB disease in patients with hematologic malignancies is 2-40 times that of the 
general population. The diagnosis of TB in these patients is often challenging as they often present 
clinical characteristics that are distinct to those of patients without any other underlying disease. 
Mortality due to TB is higher. Therefore, it is recommended to diagnose latent TB infection and 
consider preventive therapy that could avoid the progression from a latent state to active TB 
disease. There are currently two methods for diagnosing latent TB infection: the Tuberculin Skin 
Test (TST) and the Interferon-Gamma Release Assays (IGRA). Due to the lack of sensitivity in 
patients with immunodeficient conditions, a combined TST-IGRA testing is probably the best way 
for latent TB diagnosis in order to gain sensitivity. Treatment of latent TB infection and TB disease 
should follow the general principles to that in the general population.  
Introduction. Tuberculosis (TB) ranks as one of the 
leading causative diseases of mortality worldwide, with 
8.6 million of new cases in 2012 and 1.3 million deaths 
attributable to the disease.
1
 Moreover, it is estimated 
that one third of the world’s population is infected by 
M. tuberculosis, which involves an eventual risk of 
progressing to active TB. Patients with 
immunosuppression, either due to underlying disease 
or of drug origin, are especially susceptible to 
developing the disease.
2
 In this article we perform a 
general overview of the clinical and epidemiological 
characteristics of TB in patients with haematological 
malignancies (HM), as well as its diagnosis and 
treatment. 
 
Pathogenesis of Tuberculosis. M. tuberculosis is the 
causative agent of TB. It is an acid-fast bacillus, 
weakly gram-positive and belongs to the genus 
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Mycobacterium that includes more than 50 species.
3
 M. 
tuberculosis is a member of the M. tuberculosis 
complex. Only a few members of the M. tuberculosis 
complex are able to cause the disease in humans: M. 
tuberculosis, M. bovis, M. africanum, M. canetii, and 
M. caprae, being M. tuberculosis the responsible for 
the vast majority of TB cases in humans.
4-7
 As with the 
other species of the genus Mycobacterium, M. 
tuberculosis has a cell wall that is very rich in lipids 
(up to 40%), which makes it difficult to stain because 
of its acid-alcohol resistance. This characteristic has 
been the historical basis for its microbiological 
diagnosis by selective staining. Its rate of growth is 
very slow, even in specific media. Its generation time is 
around 18 hours, which is extremely long when 
compared to other species with a high prevalence of 
infection, such as S. pneumoniae or E. coli (20-30 
minutes).
8
 Together with its ability to evade the human 
immune response, it is precisely the characteristic slow 
replication of M. tuberculosis that makes this species 
so difficult to eliminate and is probably the best 
explanation for its high historical prevalence.  
Infection by M. tuberculosis starts with inhalation 
of droplets of 1-5 µm in diameter (Flügge droplets) that 
contain tubercle bacilli from a person with pulmonary 
TB.
9,10
 There are also other less usual alternative routes 
of transmission, such as the digestive tract, typical of 
M. bovis, through the ingestion of contaminated milk 
from infected livestock lacking proper veterinary 
disease control.  
After reaching the alveolar space one of the 
following three scenarios can occur: 
· Direct elimination of the bacillus.
11
  
· Latent tuberculosis infection (LTBI) in which the 
tubercle bacillus resists the bactericidal mechanisms of 
alveolar macrophages, although without causing the 
disease.
12,13
 In this situation, the immune response is 
able to contain the bacillus, but not to eliminate it. 
When the immune response is not able to contain 
M. tuberculosis, there is a development of TB disease, 
resulting in active TB. This situation can occur some 
months after initial infection (primary TB) or after 
reactivation of a prior LTBI (post-primary TB).  
Overall, around 10% of people infected will go on 
to develop active TB,
2,14
 half of these within the first 
two years of exposure to the bacillus.
15
 
The major immune response to infection by M. 
tuberculosis is focused on the type 1 helper T 
lymphocytes (Th1) capable of synthesizing interferon-
gamma (IFN-γ) and other cytokines, which manage to 
contain M. tuberculosis in a latent state without active 
replication. The final situation between LTBI and 
active TB will depend upon the balance established 
between the immune response and the bacteria. 
According to the predominance of one or the other, 
either a potentially persistent latent state will be 
established or active TB disease will be generated. 
However, the concept of latent state-disease should not 
be understood as exclusively unidirectional 
compartments. There is a dynamic balance than can be 
bidirectional, and even includes “frontier” situations 
between both states, for which terms like “subclinical 




Risk of Developing Tuberculosis in Patients with 
Haematological Malignancies. As mentioned above, 
although the “frontier” between LTBI and active TB is 
not always clear or well defined, there is a series of 
individual and epidemiological situations that favour 
the acquisition of infection and/or development of the 
disease, such as HIV infection, recent exposure to a 




Despite the heterogeneity of the immunological 
substrate presented depending on the specific type of 
malignancy, patients with HM have an underlying 
immunological deficiency that facilitates the 
emergence of infections.
19,20
 Alteration in the Th1 cell 
response of the HM itself or that caused by 
antineoplastic chemotherapy or hematopoietic stem cell 
transplantation (frequently associated to the 
administration of high doses of corticosteroids) lead to 
an impaired immune response that particularly 
promotes the progression from LTBI to active TB.
21,22
 
For more than forty years, it has been known in 
clinical practice that patients with malignancies, 
especially those with HM, have a higher risk of 
developing TB than the general population.
21,23-28
 Table 
1 gives details of some of the most significant studies 
that have analysed the risk of patients developing TB 
(search strategy in Pubmed with keywords: 
(“tuberculosis” or “latent tuberculosis infection”) and 
(“hematologic neoplasms” or “lymphoma”, 
“leukemia”, “multiple myeloma”, “stem cell 
transplantation”), as well as relevant references 




The risk of developing TB can vary depending on 
the type of HM. Some authors have analysed this 
aspect, but the results of the studies differ. In a study 
undertaken in Brazil of more than 900 patients with 
HM, Silva FA et al found that Chronic Lymphocytic 
Leukemia (CLL) was the disease that showed a greater 
susceptibility to developing TB. In this same study, 
treatment with corticoids and fludarabine was also 
associated to a higher risk of developing the disease.
33
 
However, in a retrospective study of around 3000 
onco-hematological patients, Chen CY et al found that 
patients with Acute Myeloid Leukemia had a  
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Table 1. Studies that have evaluated the risk of tuberculosis in patients with haematological malignancies 
Reference Setting RR Comments  
Libshitz HI29 USA 9.0 Cancer patients (including HM)  
de la Cámara30 Spain 2.95 Allogenic Stem Cell Transplantation  
Kamboj M27 USA 40 
Highest rate among Stem Cell 
Transplant Recipients 
 
Mishra P31 India 23 
Patients with acute leukemia. Highest 
rate in AML 
 
Stefan DC26 South Africa 22 Children with LLA  
Chen CY32 Taiwan  2.05   
Wu CY21 Taiwan  3.22
* Non-Hodgkin Lymphomas and 
Leukaemias 
 
RR: Relative Risk compared to the general population. AML: Acute Myeloid Leukemia. HM: Haematological Malignancies. *: Hazard Ratio 
 
significantly higher incidence of TB disease than other 




Diagnosis of Latent Tuberculosis Infection. The aim 
of diagnosing LTBI in patients with HM is the early 
detection of infection by M. tuberculosis while still in 
the latent phase, so treatment can be undertaken that 
eliminates the bacillus before the immune conditions 
deteriorate and the risk of TB reactivation increases. 
Currently, there are three commercial diagnostic 
tests for LTBI: the Tuberculin Skin Test (TST), which 
for decades was the only method for detecting TB 
infection, and two techniques introduced relatively 
recently that are based on the detection of interferon-
gamma (IFN-G) released from sensitized lymphocytes 
against specific antigens of M. tuberculosis: 
Quantiferon
®
-TB Gold in-Tube (QFT) and T-
SPOT
®
.TB (T-SPOT). These are all indirect methods 
of measuring infection by M. tuberculosis, as they 
detect the existence of an immune response against the 
bacillus as a surrogate marker of infection.
34
 
The TST carried out using the Mantoux technique, 
measures the cell-mediated immune response against a 
standardized dose of purified protein derivative of 
tuberculin (PPD) injected into the dermis of the 
forearm of the patient. The existence of a palpable 
induration reaction after 48-72 hours, larger than 5, 10 
or 15 mm, depending on the immune status of the 
patient, BCG vaccination and the epidemiological TB 
context, is suggestive of infection by M. 
tuberculosis.
35,36
 In general, an induration ≥10mm is 
considered to be indicative of LTBI in patients with 
HM.
37,38
 The major drawback of the TST is that most 
of the antigens present in PPD are not specific to M. 
tuberculosis, so that the specificity of the test is 
limited, especially for patients vaccinated with BCG 
(one of the most used vaccines in the world) or infected 
by non-tuberculous mycobacteria. In addition, there are 
also operational shortcomings: a second visit is 
necessary to assess the test 48-72 hours after the 
injection; measurement of the induration is subject to 
interobserver and interobserver variability; while the 
privacy of the result is on occasions difficult, because 
of the visible inflammatory reaction produced on the 
forearm. Nevertheless, it has the advantage of its low 
cost and the extensive experience gained over decades 
of use. 
The Interferon-Gamma Release Assays (IGRAs) 
measure in vitro the release of IFN-G produced by T 
lymphocytes against the stimulation of highly specific 
(but not totally specific) antigens to M. tuberculosis. In 
order to carry out these tests, it is essential to obtain a 
blood sample from the patient. For T-SPOT, the 
process is more protracted because prior separation of 
the lymphocytes of the patient is required, whereas, for 
QFT, only a simple ELISA is needed.
39
 The antigens 
used with T-SPOT are ESAT-6 and CFP-10, while for 
QFT TB7.7 is also incorporated. These antigens are not 
present in the BCG strains used for vaccination, so that 
there are no false positive results in BCG vaccinated 
patients. Nevertheless, they are present (and can, 
therefore, cause false positive results) in some species 
of non-tuberculous mycobacteria, such as M. Kansasii¸ 
M. marinum and M. szulgai.  
As mentioned above, all the current diagnostic tests 
for LTBI are based on the detection of an immune 
response by sensitized T lymphocytes that have been 
previously exposed to M. tuberculosis. Detection of 
their response against specific antigens of M. 
tuberculosis is indicative of TB infection. Therefore, 
the result obtained is only an indirect measurement of 
infection that can never be confirmed for LTBI. There 
is no available “gold standard” to evaluate the accuracy 
of these tests. 
Overall, bearing in mind these limitations, IGRAs 
have shown sensitivity at least comparable to that of 
the TST for the diagnosis of LTBI, as well as greater 
specificity.
40-42
 Moreover, numerous studies have 
already demonstrated the predictive value of IGRAs 
regarding the risk of progressing to the disease, which 
is after all the final aim of tests for detecting LTBI.
43-45
 
Taking into account the limitations for both TST and 
IGRAs, it has been suggested that a combined TST-
IGRA testing is probably the best way for LTBI 
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- Diagnosis of LTBI in patients with HM: The 
sensitivity of the tests for detecting LTBI in patients 
with underlying immunodeficiency is lower than that in 
patients with conserved immunity.
47
 But in contrast to 
patients with immunosuppression due to HIV, immune-
mediated inflammatory disorders or pharmaceutical 
drugs, the number of studies that have evaluated the 
value of IGRAs in patients with HM is much more 
limited. Piana et al compared TST and T-SPOT in 138 
Italian onco-hematological patients who had been in 
contact with a smear-positive TB patient. Of these 
patients, 17% were positive to the TST as against 44% 
who were positive to the T-SPOT test. Interestingly, a 
direct relationship was found between a positive T-
SPOT result and the degree of exposure to the index 
case of TB, which suggests that the T-SPOT test has 
greater sensitivity than the TST in the diagnosis of 
LTBI in onco-hematological patients.
48
 Richeldi et al 
found a similar result in 95 Italian patients with HM, 
who simultaneously undertook the TST, QFT and T-
SPOT tests. The percentage of positive results for 
IGRAs was significantly higher than that for the TST 
(26% for QFT, 18% for T-SPOT compared to 10% for 
the TST). However, this study did not analyse the 
correlation between the result of the tests and the 
degree of exposure (i.e. making it difficult to 
distinguish betweent rue positive result and a false 
positive one). The authors themselves recommend 
caution when interpreting the results, as it cannot be 
definitely stated that IGRAs have greater sensitivity 
than the TST for detecting LTBI in this group of 
patients.
49
 A recent study by Moon SM et al compared 
the TST and QFT in 244 South Korean patients who 
were candidates for hematopoietic stem cell 
transplantation. In contrast to the previous studies 
carried out with Italian patients, most of the patients 
had been vaccinated with BCG. The percentage of 
positive results was not significantly different (10% for 




- Indeterminate results: In addition to evaluating the 
production of IFN-G by T-lymphocytes in response to 
M. tuberculosis antigens, IGRAs also evaluate the 
production of IFN-G against a mitogen 
(Phytohemaglutinin, positive control) and a test tube 
without any antigen (null, negative control). If the 
patient has an immune response disorder, either due to 
lack of productions of IFN-G against the mitogen or 
due to an overproduction against the null control tube, 
an indeterminate result is produced, which means that 
the result obtained cannot be evaluated. 
Immunosuppressed patients present a higher 
prevalence of indeterminate results both with the T-
SPOT test and QFT, normally because of a lack of 
responses to the positive control with mitogen. In a 
recent report of 18 children with cancer or primary 
immunodeficiencies who had been exposed to an adult 
with smear-positive TB, the T-SPOT test provided 
fewer indeterminate results than the QFT.
51
 In another 
study undertaken with 34 South African children with 
different types of cancer (21 with HM), indeterminate 
results were found in 4 patients (11%) with the T-
SPOT technique, as against 15% when using the QFT. 
It should be stressed that, because of various problems, 
the T-SPOT technique could not be carried out with a 
further 7 children (21%) in this same study. 
Indeterminate results were more frequent in children 





Treatment of Latent Tuberculosis Infection. As 
mentioned earlier, patients with HM have a higher risk 
of TB reactivation than the general population. 
However, this does not necessarily mean that all 
patients with LTBI and HM should receive treatment 
for LTBI because, despite this higher risk, most 
patients with LTBI will never develop TB disease, 
even without preventive treatment. Treatment of LTBI 
may not be appropriate in certain situations such as a 
short life expectancy (which is the case for a relatively 
important percentage of patients with HM); when 
medical drug toxicity could be high, as in patients with 
underlying liver disease;
53
 or in patients for whom 
adherence to treatment could be suboptimal.
54
decision 
should be made in an individualized and consensual 
way with each patient regarding whether or not to take 
treatment for LTBI. In our experience, the toxicity 
caused by the treatment of LTBI in patients with HM is 
no different to that for the population with other 
indications for treatment of LTBI.
55
 
- Treatment regimens: There are several preventive 
treatment regimens with recognized efficacy in 
different risk situations for developing TB
46,56,57
 (Table 
2). However, none of these has evaluated the efficacy 
of treatment specifically among patients with HM. 
Therefore, the recommendations for the treatment of 
LTBI in onco-hematological patients are based on 
studies carried out among patients in other risk 
situations for developing the disease.
58-61
 Prior to 
starting treatment of LTBI, it is necessary to exclude 
active TB. If there is an active TB, and a preventive 
treatment is started with only one drug, the patient is at 
high risk of generating a TB that is resistant to that 
drug. 
The treatment of LTBI that has been most studied 
and has a proven efficacy is that with isoniazid (H). 
This treatment regimen should last between 6 and 9 
months, while having the prolonged treatment the
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Table 2. Treatments recommended for Latent Tuberculosis Infection  
DRUG REGIMEN LENGTH OF TREATMENT ADULT DOSE SIDE EFFECTS COMMENTS 
INH 6-9 months 300mg/day 
Hepatotoxicity 
Neurotoxicity 
RIF 4-6 months 600 mg/day 
Hepatotoxicity 
Thrombopenia 
Interaction with other drugs 
INH+RIF 3 months Idem as above Not recommended in HIV 




PZA+RIF   No longer used because of toxicity 
INH: isoniazid; RIF: rifampicin; RPT: rifapentine; PZA: pyrazinamide; DOT: Directly Observed Therapy. 
 
greatest preventive efficacy. The 9 months regimen 
reaches a protective efficacy against TB reactivation of 
90% and is probably the best duration for LTBI 
treatment with isoniazid.
37,62,63
 An alternative is the use 
of rifampicin (R) for 4 months, which is especially 
recommended in cases of resistance to H.
64,65
 There is a 
third regimen of similar efficacy consisting of a 
combination of HR for 3 months. The shorter length of 
the treatment makes adherence easier.
66
 In a meta-
analysis performed by Ena J et al in 2005, the 
development of active TB was found to be equivalent 
with short-course regimen with HR as compared to 
standard therapy with isoniazid (pooled risk difference: 
0%; 95% CI: -1% to 2%).
67
 Finally, there is another 
shorter (3 months) effective alternative regimen with a 
single weekly dose of H and rifapentine (a rifamycin 




Active Tuberculosis. Infections are one of the most 
common complications of HM and are one of the main 
causes of mortality. Although bacteria are usually the 
aetiological agents,
19,69
 together with fungi and viruses 
to a lesser extent, the aetiology of other germs should 
always be considered. This applies to disease caused by 
M. tuberculosis, especially in the non-neutropenic 




- Clinical aspects: TB patients with different types 
of cancer, including those with HM, often present 
clinical characteristics that are distinct to those of 
patients without any other underlying disease. The 
extra pulmonary form of TB is more frequent in these 
patients
20,25
 and in bone marrow transplant recipients.
73
 




- Diagnosis: The diagnostic gold-standard for active 
TB relies on the detection of M. tuberculosis by culture 
or molecular methods.
74
 Microscopy detection of acid-
fast bacilli is a cheap and simple method for diagnosing 
TB, however, this method has limited sensitivity of 
50% or less in sputum samples or even less in extra-
pulmonary locations of TB.
75
 In addition, the presence 
of acid-fast bacilli is not always indicative of M. 
tuberculosis as other mycobacteria species have also 
this staining property. Nucleic acid amplification tests 
are increasingly used for rapid diagnosis of TB.
76
 One 
of these (Gen Xpert MTB/RIF®) is endorsed by the 
World Health Organization due to its simplicity of use, 
high sensitivity and because it also provides rapid 
diagnosis of TB. Additionally, this method, detects an 
eventual resistance to rifampicin in less than two hours 
after obtaining the sample.
77-79
 The diagnosis of non-
pulmonary TB is often challenging, because it is not 
easy to obtain microbiological confirmation in such 
cases. It is not uncommon to recommend starting an 
empirical specific anti-tuberculosis treatment. 
Detection in urine of lipoarabinomannan (LAM), a 
constituent of the cell wall of M. tuberculosis, has 
shown its utility for TB diagnosis in HIV-infected 
patients. However, this method has not been validated 
in patients with HM.
80
 The suspected diagnosis of 
lymph node TB is especially difficult, because its 
presentation is similar to that of lymphoma. The 
presence of radiological hypodensity in the centre of 
the node is suggestive of necrosis and tuberculous 
aetiology, but by no means is it diagnostic.
81
 In cases 
where microbiological confirmation is not possible, 
there are various clinical and radiological 
characteristics that are suggestive of tuberculous 
aetiology.
82-84
 Nevertheless, for a definitive diagnosis, 
needle aspiration or needle biopsy is always required to 
obtain samples and to culture them in specific 
mycobacteria media. 
As with the TST, the sensitivity of IGRAs for the 
diagnosis of TB is low in patients with 
immunosuppression. In a study in South Korea of 
patients with smear negative pulmonary TB and 
associated immunosuppression, the diagnostic 
sensitivity of T-SPOT and QFT among patients with a 
tumoral disease was 69% and 58%, respectively. These 
percentages were higher (although not reaching 
statistical significance) to the 37% obtained with the 
TST. In this same study, the authors conclude that 
neither the IGRAs nor the TST have value as a single 
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Treatment of Active Tuberculosis. The treatment of 
TB is based on two main principles: 1) the combination 
of at least 3-4 drugs, which avoids the emergence of 
bacterial resistance and 2) the need for prolonged 
treatments (of at least 6 months) to prevent relapses.
86
 
The standard treatment regimen for previously 
untreated TB is the administration for two months of 
isoniazid, rifampicin, pyrazinamide and ethambutol 
(2HRZE) (intensive phase of treatment) followed by a 
continuation phase of 4 months with isoniazid and 
rifampicin (4HR).
87,88
 Ideally, the administration of the 
dose should be in a combined formulation (there are 
commercially available combinations of the 4 drugs in 
single presentations), in daily doses (although there are 
valid treatment regimens with doses taken two or three 
times a week), and should include measures that 
promotes adherence for the patient. Cure rates for 
sensitive strains with this regimen are higher than 
98%.
86,89
 Rifampin is a potent inducer of both 
cytochrome P-450 oxidative enzymes and the P-
glycoprotein transport system and may, therefore, 
decrease the level or effect of some chemotherapeutic 
agents prescribed in HM patients. Interactions of 
rifampin with bortezomib, doxorubicin, vincristine, 




In certain circumstances, the standard regimen of 
2HRZE+4HR cannot be used. The following are some 
of the most common causes: 




If isoniazid cannot be used, one of the following 
regimens is recommended: 6-9RZE or 2RZE+10RE. 
In the situations where the rifampin cannot be used, 
the length of treatment should be extended up to 18 
months. In addition, during the intensive phase, 
pyrazinamide should be included, as well as an 
injectable drug (preferably streptomycin, although 
amikacin; kanamycin and capreomycin also have a 
good anti-tubercular activity), or a third-generation 
quinolone (moxifloxacin) when there is a high bacillary 
burden. 
If ethambutol cannot be used: 2HRZ+4HR. 
If pyrazinamide cannot be used: 2HRE+7HR. 
When neither isoniazid nor rifampicin can be used, 
combined resistance to these two drugs is known as 
Multidrug-resistant TB (MDR-TB) and is particularly 
challenging situation, as these two drugs have the 
highest activity against M. tuberculosis. In such 
scenarios, treatment should be individualized taking 
into account sensitivity to the other available drugs, 
and to the previous TB treatments. The length of the 
treatment should be at least 18-24 months and must be 
supervised by doctors with relevant experience. The 
treatment should include an injectable drug 
(streptomycin, kanamycin, amikacin or capreomycin) 
and a quinolone.
93,94
 The strains of MDR-TB that also 
present additional resistance to any quinolone and any 
of the three injectable drugs are known as extensively 
drug resistant TB (XDR-TB). In these circumstances, 




2· Slow microbiological response  
The persistence of positive sputum cultures after 
two months of treatment has been related to an 
unacceptably high relapse rate. Therefore, it is 
recommended that the length of treatment be extended 
to a total of 9 months (2HRZE+7HR) in patients with 
drug-susceptible strains who have cavitation on the 
initial or follow-up chest radiograph and are culture-
positive at the second month of treatment .
98
 
3· Other scenarios 
In patients with HIV co-infection and absence of 
antiretroviral treatment, in cases of silicosis, or in cases 
of bone and joint or meningeal TB, the prolongation of 
treatment beyond 6 months has been suggested with 
the aim of preventing relapses.
99,100
  
For patients with TB and HM, there is no evidence 
that the regimen or length of treatment should differ 
from the standard regimen.  
 
Acknowledgments. We acknowledge the European 
Union Seventh Framework Programme 




1. World, Health, Organization. Global Tuberculosis Report 2013; 
WHO/HTM/TB/2013.11. Geneva, Switzerland: World Health 
Organization; 2013.  
2. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N 
Engl J Med 2013;368:745-55. 
3. Grange JM. The genus Mycobacterium and the Mycobacterium 
tuberculosis complex. In: Schaaf HS ZA, ed. Tuberculosis A 
comprehensive clinical reference: Elsevier Inc; 2009.  
4. Assam Assam JP, Penlap Beng V, Cho-Ngwa F, et al. 
Mycobacterium tuberculosis is the causative agent of tuberculosis 
in the southern ecological zones of Cameroon, as shown by genetic 
analysis. BMC Infect Dis 2013;13:431. 
http://dx.doi.org/10.1186/1471-2334-13-431 
5. Ueyama M, Chikamatsu K, Aono A, et al. Sub-speciation of 
Mycobacterium tuberculosis complex from tuberculosis patients in 
Japan. Tuberculosis (Edinb) 2014;94:15-9. 
http://dx.doi.org/10.1016/j.tube.2013.09.006 
6. de Jong BC, Antonio M, Gagneux S. Mycobacterium africanum--
review of an important cause of human tuberculosis in West 
Africa. PLoS Negl Trop Dis 2010;4:e744.  
7. Rodriguez E, Sanchez LP, Perez S, et al. Human tuberculosis due 
to Mycobacterium bovis and M. caprae in Spain, 2004-2007. Int J 
Tuberc Lung Dis 2009;13:1536-41.  
8. FitzGerald D, Sterling T, Hass D. Mycobacterium tuberculosis. In: 
Mandell, Douglas, Bennett, eds. Principles and Practice of 
Infectious Diseases. 7th ed: Churchill Livingstone, Elsevier; 
Mediterr J Hematol Infect Dis 2014; 6: Open Journal System  
 
2010:3129-63.  
9. Caminero JA. A Tuberculosis Guide for Specialist Physicians: 
International Union against Tuberculosis and Lung Disease; 2003.  
10. Mastorides SM, Oehler RL, Greene JN, Sinnott JT, Kranik M, 
Sandin RL. The detection of airborne Mycobacterium tuberculosis 
using micropore membrane air sampling and polymerase chain 
reaction. Chest 1999;115:19-25. 
http://dx.doi.org/10.1378/chest.115.1.19   
11. Ewer K, Millington K, Deeks J, Alvarez L, Bryant G, Lalvani A. 
Dynamic antigen-specific T-cell responses after point-source 
exposure to Mycobacterium tuberculosis. Am J Respir Crit Care 
Med 2006;174:831-9. http://dx.doi.org/10.1164/rccm.200511-
1783OC  
12. Cardona PJ. A dynamic reinfection hypothesis of latent 
tuberculosis infection. Infection 2009;37:80-6. 
http://dx.doi.org/10.1007/s15010-008-8087-y   
13. Barrios-Payán J, Saqui-Salces M, Jeyanathan M, et al. 
Extrapulmonary Locations of Mycobacterium tuberculosis DNA 
During Latent Infection. Journal of Infectious Diseases 
2012;206:1194-205. http://dx.doi.org/10.1093/infdis/jis381   
14. Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors for 
tuberculosis. Pulm Med 2013;2013:828939. 
http://dx.doi.org/10.1155/2013/828939   
15. Vynnycky E, Fine PE. Lifetime risks, incubation period, and serial 
interval of tuberculosis. Am J Epidemiol 2000;152:247-63. 
http://dx.doi.org/10.1093/aje/152.3.247   
16. Russell D, Cardona P, Kim M, Allain S, Altare F. Foamy 
macrophages and the progression of the human tuberculosis 
granuloma. Nat Immunol 2009;10:943-8. 
http://dx.doi.org/10.1038/ni.1781   
17. Achkar JM, Jenny-Avital ER. Incipient and subclinical 
tuberculosis: defining early disease states in the context of host 
immune response. J Infect Dis 2011;204 Suppl 4:S1179-86 
http://dx.doi.org/10.1093/infdis/jir451  
18. Esmail H, Barry CE, 3rd, Wilkinson RJ. Understanding latent 
tuberculosis: the key to improved diagnostic and novel treatment 
strategies. Drug Discov Today 2012;17:514-21. 
http://dx.doi.org/10.1016/j.drudis.2011.12.013   
19. Pagano L, Caira M, Rossi G, et al. A prospective survey of febrile 
events in hematological malignancies. Ann Hematol 2012;91:767-
74. http://dx.doi.org/10.1007/s00277-011-1373-2   
20. Gupta A, Singh M, Singh H, et al. Infections in acute myeloid 
leukemia: an analysis of 382 febrile episodes. Med Oncol 
2010;27:1037-45. http://dx.doi.org/10.1007/s12032-009-9330-9   
21. Wu CY, Hu HY, Pu CY, et al. Aerodigestive tract, lung and 
haematological cancers are risk factors for tuberculosis: an 8-year 
population-based study. Int J Tuberc Lung Dis 2011;15:125-30.  
22. Al-Anazi KA, Al-Jasser AM, Evans DA. Infections caused by 
Mycobacterium tuberculosis in patients with hematological 
disorders and in recipients of hematopoietic stem cell transplant, a 
twelve year retrospective study. Ann Clin Microbiol Antimicrob 
2007;6:16. http://dx.doi.org/10.1186/1476-0711-6-16   
23. Cliffton EE, Irani BB. Pulmonary tuberculosis and cancer. N Y 
State J Med 1970;70:274-8.  
24. Preventive treatment for tuberculous infection. Recommendations 
of the National Communicable Disease Center. Arch Environ 
Health 1970;20:535-6. 
http://dx.doi.org/10.1080/00039896.1970.10665635   
25. Kaplan MH, Armstrong D, Rosen P. Tuberculosis complicating 
neoplastic disease. A review of 201 cases. Cancer 1974;33:850-8. 
http://dx.doi.org/10.1002/1097-0142(197403)33:3<850::AID-
CNCR2820330334>3.0.CO;2-H   
26. Stefan DC, Kruis AL, Schaaf HS, Wessels G. Tuberculosis in 
oncology patients. Ann Trop Paediatr 2008;28:111-6. 
http://dx.doi.org/10.1179/146532808X302125   
27. Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients 
with cancer. Clin Infect Dis. United States2006:1592-5.  
28. Chen CY, Sheng WH, Lai CC, et al. Mycobacterial infections in 
adult patients with hematological malignancy. Eur J Clin Microbiol 
Infect Dis 2011.  
29. Libshitz HI, Pannu HK, Elting LS, Cooksley CD. Tuberculosis in 
cancer patients: an update. J Thorac Imaging 1997;12:41-6. 
http://dx.doi.org/10.1097/00005382-199701000-00006 
30. de la Cámara R, Martino R, Granados E, et al. Tuberculosis after 
hematopoietic stem cell transplantation: incidence, clinical 
characteristics and outcome. Spanish Group on Infectious 
Complications in Hematopoietic Transplantation. Bone Marrow 
Transplant 2000;26:291-8.  
http://dx.doi.org/10.1038/sj.bmt.1702506   
31. Mishra P, Kumar R, Mahapatra M, et al. Tuberculosis in acute 
leukemia: a clinico-hematological profile. Hematology 
2006;11:335-40. http://dx.doi.org/10.1080/10245330600915818   
32. Chen CY, Sheng WH, Cheng A, et al. Clinical characteristics and 
outcomes of Mycobacterium tuberculosis disease in adult patients 
with hematological malignancies. BMC Infect Dis 2011;11:324. 
http://dx.doi.org/10.1186/1471-2334-11-324   
33. Silva FA, Matos JO, de QMFC, Nucci M. Risk factors for and 
attributable mortality from tuberculosis in patients with 
hematologic malignances. Haematologica 2005;90:1110-5.  
34. Pai M, Denkinger CM, Kik SV, et al. Gamma Interferon Release 
Assays for Detection of Mycobacterium tuberculosis Infection. 
Clin Microbiol Rev 2014;27:3-20.  
http://dx.doi.org/10.1128/CMR.00034-13   
35. Sokal JE. Editorial: Measurement of delayed skin-test responses. N 
Engl J Med 1975;293:501-2.  
http://dx.doi.org/10.1056/NEJM197509042931013   
36. Lee E, Holzman RS. Evolution and current use of the tuberculin 
test. Clin Infect Dis 2002;34:365-70. 
http://dx.doi.org/10.1086/338149  
37. Targeted tuberculin testing and treatment of latent tuberculosis 
infection. American Thoracic Society. MMWR Recomm Rep 
2000;49:1-51.  
38. Pai M, Kunimoto D, Frances J, Dick M. Diagnosis of Latent 
Tuberculosis Infection. Canadian Tuberculosis Standards. 7th ed: 
Canadian Thoracic Society; 2013 
39. Pai M, Riley LW, Colford JM. Interferon-gamma assays in the 
immunodiagnosis of tuberculosis: a systematic review. Lancet 
Infect Dis 2004;4:761-76. http://dx.doi.org/10.1016/S1473-
3099(04)01206-X   
40. Trajman A, Steffen RE, Menzies D. Interferon-Gamma Release 
Assays versus Tuberculin Skin Testing for the Diagnosis of Latent 
Tuberculosis Infection: An Overview of the Evidence. Pulm Med 
2013;2013:601737. http://dx.doi.org/10.1155/2013/601737   
41. Schluger NW. Advances in the diagnosis of latent tuberculosis 
infection. Semin Respir Crit Care Med 2013;34:60-6. 
http://dx.doi.org/10.1055/s-0032-1333545   
42. Mu-oz L, Santin M. Interferon-? release assays versus tuberculin 
skin test for targeting people for tuberculosis preventive treatment: 
an evidence-based review. J Infect 2013;66:381-7. 
http://dx.doi.org/10.1016/j.jinf.2012.12.005   
43. Diel R, Loddenkemper R, Nienhaus A. Predictive value of 
interferon-? release assays and tuberculin skin testing for 
progression from latent TB infection to disease state: a meta-
analysis. Chest 2012;142:63-75. http://dx.doi.org/10.1378/chest.11-
3157   
44. Haldar P, Thuraisingam H, Patel H, et al. Single-step 
QuantiFERON screening of adult contacts: a prospective cohort 
study of tuberculosis risk. Thorax 2013;68:240-6. 
http://dx.doi.org/10.1136/thoraxjnl-2011-200956   
45. Machingaidze S, Verver S, Mulenga H, et al. Predictive value of 
recent QuantiFERON conversion for tuberculosis disease in 
adolescents. Am J Respir Crit Care Med 2012;186:1051-6. 
http://dx.doi.org/10.1164/rccm.201206-1134OC   
46. González-Martín J, García-García J, Anibarro L, et al. [Consensus 
document on the diagnosis, treatment and prevention of 
tuberculosis]. Enferm Infecc Microbiol Clin 2010;28:297.e1-20. 
47. Redelman-Sidi G, Sepkowitz KA. IFN-? release assays in the 
diagnosis of latent tuberculosis infection among 
immunocompromised adults. Am J Respir Crit Care Med 
2013;188:422-31. http://dx.doi.org/10.1164/rccm.201209-1621CI   
48. Piana F, Codecasa LR, Cavallerio P, et al. Use of a T-cell-based 
test for detection of tuberculosis infection among 
immunocompromised patients. Eur Respir J 2006;28:31-4. 
http://dx.doi.org/10.1183/09031936.06.00110205   
49. Richeldi L, Losi M, D'Amico R, et al. Performance of tests for 
latent tuberculosis in different groups of immunocompromised 
patients. Chest 2009;136:198-204. 
http://dx.doi.org/10.1378/chest.08-2575   
50. Moon SM, Lee SO, Choi SH, et al. Comparison of the 
QuantiFERON-TB Gold In-Tube test with the tuberculin skin test 
for detecting latent tuberculosis infection prior to hematopoietic 
stem cell transplantation. Transpl Infect Dis 2013;15:104-9. 
Mediterr J Hematol Infect Dis 2014; 6: Open Journal System  
 
http://dx.doi.org/10.1111/j.1399-3062.2012.00765.x   
51. Carvalho AC, Schumacher RF, Bigoni S, et al. Contact 
investigation based on serial interferon-gamma release assays 
(IGRA) in children from the hematology-oncology ward after 
exposure to a patient with pulmonary tuberculosis. Infection 
2013;41:827-31. http://dx.doi.org/10.1007/s15010-013-0450-y   
52. Stefan DC, Dippenaar A, Detjen AK, et al. Interferon-gamma 
release assays for the detection of Mycobacterium tuberculosis 
infection in children with cancer. Int J Tuberc Lung Dis 
2010;14:689-94.  
53. Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid 
hepatotoxicity associated with treatment of latent tuberculosis 
infection: a 7-year evaluation from a public health tuberculosis 
clinic. Chest 2005;128:116-23.  
http://dx.doi.org/10.1378/chest.128.1.116   
54. Anibarro L, Casas S, Paz-Esquete J, et al. Treatment completion in 
latent tuberculosis infection at specialist tuberculosis units in 
Spain. Int J Tuberc Lung Dis 2010;14:701-7.  
55. Sánchez-García EM, Gamallo R, Blanco-Moure A, Viejo MA, 
Amador L, Anibarro L. Toxicity and adherence to treatment for 
latent tuberculosis infection in patients with hematologic 
malignancies. Infection 2013;41:903-7.  
http://dx.doi.org/10.1007/s15010-013-0489-9   
56. Chee CB, Sester M, Zhang W, Lange C. Diagnosis and treatment 
of latent infection with Mycobacterium tuberculosis. Respirology 
2013;18:205-16. http://dx.doi.org/10.1111/resp.12002   
57. Horsburgh CR, Rubin EJ. Clinical practice. Latent tuberculosis 
infection in the United States. N Engl J Med 2011;364:1441-8. 
http://dx.doi.org/10.1056/NEJMcp1005750   
58. Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled 
trial of the prophylactic use of isoniazid among household contacts. 
Am Rev Respir Dis 1962;85:490-510.  
59. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of 
community-wide isoniazid prophylaxis in Alaska. Am Rev Respir 
Dis 1967;95:935-43.  
60. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. 
Effectiveness of recommendations to prevent reactivation of latent 
tuberculosis infection in patients treated with tumor necrosis factor 
antagonists. Arthritis Rheum 2005;52:1766-72. 
http://dx.doi.org/10.1002/art.21043   
61. Cruz AT, Ahmed A, Mandalakas AM, Starke JR. Treatment of 
Latent Tuberculosis Infection in Children. Journal of the Pediatric 
Infectious Diseases Society 2013;2:248-58. 
http://dx.doi.org/10.1093/jpids/pit030   
62. Snider DE, Caras GJ, Koplan JP. Preventive therapy with 
isoniazid. Cost-effectiveness of different durations of therapy. 
JAMA 1986;255:1579-83.  
http://dx.doi.org/10.1001/jama.1986.03370120057023   
63. Comstock GW. How much isoniazid is needed for prevention of 
tuberculosis among immunocompetent adults? Int J Tuberc Lung 
Dis 1999;3:847-50.  
64. Villarino ME, Ridzon R, Weismuller PC, et al. Rifampin 
preventive therapy for tuberculosis infection: experience with 157 
adolescents. Am J Respir Crit Care Med 1997;155:1735-8. 
http://dx.doi.org/10.1164/ajrccm.155.5.9154885   
65. Ziakas P, Mylonakis E. 4 months of rifampin compared with 9 
months of isoniazid for the management of latent tuberculosis 
infection: a meta-analysis and cost-effectiveness study that focuses 
on compliance and liver toxicity. Clin Infect Dis 2009;49:1883-9. 
http://dx.doi.org/10.1086/647944   
66. Spyridis N, Spyridis P, Gelesme A, et al. The effectiveness of a 9-
month regimen of isoniazid alone versus 3- and 4-month regimens 
of isoniazid plus rifampin for treatment of latent tuberculosis 
infection in children: results of an 11-year randomized study. Clin 
Infect Dis 2007;45:715-22. http://dx.doi.org/10.1086/520983   
67. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, 
compared with standard therapy with isoniazid, for latent 
tuberculosis infection: a meta-analysis. Clin Infect Dis 
2005;40:670-6. http://dx.doi.org/10.1086/427802   
68. Sterling TR, Villarino ME, Borisov AS, et al. Three Months of 
Rifapentine and Isoniazid for Latent Tuberculosis Infection. New 
England Journal of Medicine 2011;365:2155-66. 
http://dx.doi.org/10.1056/NEJMoa1104875   
69. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice 
guideline for the use of antimicrobial agents in neutropenic patients 
with cancer: 2010 Update by the Infectious Diseases Society of 
America. Clin Infect Dis 2011;52:427-31. 
http://dx.doi.org/10.1093/cid/ciq147   
70. Srivastava VM, Krishnaswami H, Srivastava A, Dennison D, 
Chandy M. Infections in haematological malignancies: an autopsy 
study of 72 cases. Trans R Soc Trop Med Hyg 1996;90:406-8. 
http://dx.doi.org/10.1016/S0035-9203(96)90524-6   
71. Advani SH, Banavali SD. Pattern of infection in hematologic 
malignancies: an Indian experience. Rev Infect Dis 1989;11 Suppl 
7:S1621-8. (CDC) CfDCaP. Updated guidelines for the use of 
nucleic acid amplification tests in the diagnosis of tuberculosis. 
MMWR Morb Mortal Wkly Rep 2009;58:7-10.  
72. Jagarlamudi R, Kumar L, Kochupillai V, Kapil A, Banerjee U, 
Thulkar S. Infections in acute leukemia: an analysis of 240 febrile 
episodes. Med Oncol 2000;17:111-6.  
http://dx.doi.org/10.1007/BF02796205   
73. George B, Mathews V, Srivastava V, Srivastava A, Chandy M. 
tuberculosis among allogeneic bone marrow transplant recipients in 
India. Bone Marrow Transplant 2001;27:973-5. 
http://dx.doi.org/10.1038/sj.bmt.1702993   
74. (CDC) CfDCaP. Updated guidelines for the use of nucleic acid 
amplification tests in the diagnosis of tuberculosis. MMWR Morb 
Mortal Wkly Rep 2009;58:7-10. 
75. Achkar JM, Lawn SD, Moosa MY, Wright CA, Kasprowicz VO. 
Adjunctive tests for diagnosis of tuberculosis: serology, ELISPOT 
for site-specific lymphocytes, urinary lipoarabinomannan, string 
test, and fine needle aspiration. J Infect Dis 2011;204 Suppl 
4:S1130-41. http://dx.doi.org/10.1093/infdis/jir450   
76. Leung CC, Lange C, Zhang Y. Tuberculosis: Current state of 
knowledge: An epilogue. Respirology 2013;18:1047-55.  
77. Mu-oz L, Moure R, Porta N, et al. GeneXpert® for smear-negative 
pulmonary tuberculosis: does it play a role in low-burden 
countries? Diagn Microbiol Infect Dis 2013;75:325-6. 
http://dx.doi.org/10.1016/j.diagmicrobio.2012.11.011   
78. Bowles EC, Freyée B, van Ingen J, Mulder B, Boeree MJ, van 
Soolingen D. Xpert MTB/RIF®, a novel automated polymerase 
chain reaction-based tool for the diagnosis of tuberculosis. Int J 
Tuberc Lung Dis 2011;15:988-9.  
http://dx.doi.org/10.5588/ijtld.10.0574   
79. World, Health, Organization. Policy statement: automated real-
time nucleic acid amplification technology for rapid and 
simultaneous detection of tuberculosis and rifampicin resistance: 
Xpert MTB/RIF system; WHO/HTM/TB/2011.4. Geneva, 
Switzerland: World Health Organization; 2011.  
80. Lawn SD, Dheda K, Kerkhoff AD, et al. Determine TB-LAM 
lateral flow urine antigen assay for HIV-associated tuberculosis: 
recommendations on the design and reporting of clinical studies. 
BMC Infect Dis 2013;13:407. http://dx.doi.org/10.1186/1471-
2334-13-407   
81. King AD, Tse GM, Ahuja AT, et al. Necrosis in metastatic neck 
nodes: diagnostic accuracy of CT, MR imaging, and US. 
Radiology 2004;230:720-6.  
http://dx.doi.org/10.1148/radiol.2303030157   
82. Chen J, Yang ZG, Shao H, et al. Differentiation of tuberculosis 
from lymphomas in neck lymph nodes with multidetector-row 
computed tomography. Int J Tuberc Lung Dis 2012;16:1686-91. 
http://dx.doi.org/10.5588/ijtld.12.0204   
83. Tang SS, Yang ZG, Deng W, Shao H, Chen J, Wen LY. 
Differentiation between tuberculosis and lymphoma in mediastinal 
lymph nodes: Evaluation with contrast-enhanced MDCT. Clin 
Radiol 2012;67:877-83.  
http://dx.doi.org/10.1016/j.crad.2012.02.006   
84. Shao H, Yang ZG, Deng W, Chen J, Tang SS, Wen LY. 
Tuberculosis versus lymphoma in the abdominal lymph nodes: a 
comparative study using contrast-enhanced MRI. Eur J Radiol 
2012;81:2513-7. http://dx.doi.org/10.1016/j.ejrad.2011.11.004   
85. Jung JY, Lim JE, Lee HJ, et al. Questionable role of interferon-? 
assays for smear-negative pulmonary TB in immunocompromised 
patients. J Infect 2012;64:188-96.  
http://dx.doi.org/10.1016/j.jinf.2011.09.008   
86. Caminero JA, Matteelli A, Lange C. Treatment of TB. 
Tuberculosis: European Respiratory Society Journals Ltd; 
2012:154-66.  
87. World, Health, Organization. Treatment of Tuberculosis 
Guidelines. WHO/HTM/TB/2009.420. 4th ed. Geneva, 
Switzerland: World Health Organization; 2010.  
88. Clinical diagnosis and management of tuberculosis, and measures 
Mediterr J Hematol Infect Dis 2014; 6: Open Journal System  
 
for its prevention and control. NICE Clinical Guideline 117: 
National Institute for Health and Clinical Excellence; 2011.  
89. Yew WW, Lange C, Leung CC. Treatment of tuberculosis: update 
2010. Eur Respir J 2011;37:441-62. 
http://dx.doi.org/10.1183/09031936.00033010   
90. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on 
rifampin, rifabutin, and rifapentine drug interactions. Current 
Medical Research and Opinion 2013;29:1-12. 
http://dx.doi.org/10.1185/03007995.2012.747952  
91. http://reference.medscape.com/drug-interactionchecker  2014. 
(Accessed 28th february 2014, 
92. World, Health, Organization. Guidelines for the programmatic 
management of drug-resistant tuberculosis. Emergency update 
2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: World 
Health Organization; 2008. 
93. Mitnick C, Bayona J, Palacios E, et al. Community-Based Therapy 
for Multidrug-Resistant Tuberculosis in Lima, Peru. New England 
Journal of Medicine 2003;348:119-28.  
http://dx.doi.org/10.1056/NEJMoa022928   
94. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug 
treatment for multidrug-resistant and extensively drug-resistant 
tuberculosis. Lancet Infect Dis 2010;10:621-9. 
http://dx.doi.org/10.1016/S1473-3099(10)70139-0   
95. Dheda K, Warren RM, Zumla A, Grobusch MP. Extensively drug-
resistant tuberculosis: epidemiology and management challenges. 
Infect Dis Clin North Am 2010;24:705-25. 
http://dx.doi.org/10.1016/j.idc.2010.05.001   
96. Tang S, Zhang Q, Yu J, et al. Extensively drug-resistant 
tuberculosis at a tuberculosis specialist hospital in Shanghai, 
China: clinical characteristics and treatment outcomes. Scand J 
Infect Dis 2011;43:280-5.  
http://dx.doi.org/10.3109/00365548.2010.548080   
97. O'Donnell MR, Padayatchi N, Kvasnovsky C, Werner L, Master I, 
Horsburgh CR. Treatment outcomes for extensively drug-resistant 
tuberculosis and HIV co-infection. Emerg Infect Dis 2013;19:416-
24. http://dx.doi.org/10.3201/eid1903.120998   
98. Blumberg HM, Burman WJ, Chaisson RE, et al. American 
Thoracic Society/Centers for Disease Control and 
Prevention/Infectious Diseases Society of America: treatment of 
tuberculosis. Am J Respir Crit Care Med 2003;167:632.  
99. Ahmad Khan F, Minion J, Al-Motairi A, Benedetti A, Harries AD, 
Menzies D. An Updated Systematic Review and Meta-analysis on 
the Treatment of Active Tuberculosis in Patients With HIV 
Infection. Clinical Infectious Diseases 2012;55:1154-63. 
http://dx.doi.org/10.1093/cid/cis630   
100. Millet JP, Orcau A, Casals M, Garcia de Olalla P, Caylà JA. 
Recurrences in tuberculosis in a cohort of human 
immunodeficiency virus-infected patients: the influence of highly 
active antiretroviral therapy. Enferm Infecc Microbiol Clin 
2013;31:227-9. http://dx.doi.org/10.1016/j.eimc.2012.08.008   
 
 
  
